AR102593A1 - Anticuerpos anti-pdgf-b y métodos de uso - Google Patents
Anticuerpos anti-pdgf-b y métodos de usoInfo
- Publication number
- AR102593A1 AR102593A1 ARP150103646A ARP150103646A AR102593A1 AR 102593 A1 AR102593 A1 AR 102593A1 AR P150103646 A ARP150103646 A AR P150103646A AR P150103646 A ARP150103646 A AR P150103646A AR 102593 A1 AR102593 A1 AR 102593A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- seq
- amino acid
- acid sequence
- pdgf
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 208000014245 Ocular vascular disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un anticuerpo que se une específicamente a PDGF-B humano, en el que el anticuerpo comprende (a) una HVR-H1 que comprende la secuencia de aminoácidos de SEC ID Nº 93, (b) una HVR-H2 que comprende la secuencia de aminoácidos de SEC ID Nº 94, (c) una HVR-H3 que comprende la secuencia de aminoácidos de SEC ID Nº 96, (d) una HVR-L1 que comprende la secuencia de aminoácidos de SEC ID Nº 98, (e) una HVR-L2 que comprende la secuencia de aminoácidos de SEC ID Nº 99, y (f) HVR-L3 que comprende la secuencia de aminoácidos de SEC ID Nº 100. Reivindicación 5: Una formulación farmacéutica que comprende un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 4 y opcionalmente un vehículo farmacéuticamente aceptable. Reivindicación 9: El uso de acuerdo con una cualquiera de las reivindicaciones 7 y 8, en el que el medicamento es para el tratamiento de una enfermedad vascular ocular, preferentemente para el tratamiento de degeneración macular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192519 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102593A1 true AR102593A1 (es) | 2017-03-08 |
Family
ID=51947140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103646A AR102593A1 (es) | 2014-11-10 | 2015-11-09 | Anticuerpos anti-pdgf-b y métodos de uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10087246B2 (es) |
| EP (1) | EP3218400A1 (es) |
| JP (1) | JP6946184B2 (es) |
| KR (1) | KR20170082520A (es) |
| CN (1) | CN107148429B (es) |
| AR (1) | AR102593A1 (es) |
| AU (1) | AU2015345322A1 (es) |
| BR (1) | BR112017009792A2 (es) |
| CA (1) | CA2963723A1 (es) |
| IL (1) | IL251286A0 (es) |
| MX (1) | MX2017005975A (es) |
| RU (1) | RU2017120361A (es) |
| SG (1) | SG11201703426PA (es) |
| TW (1) | TW201630934A (es) |
| WO (1) | WO2016075036A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| WO2016075037A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| WO2016075035A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| PL3328886T3 (pl) * | 2015-07-29 | 2021-02-08 | Allergan, Inc. | Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu |
| JP2022530442A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | アントラサイクリン抗体薬物複合体およびその使用 |
| WO2021198034A1 (en) | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
| AU2022210475A1 (en) | 2021-01-25 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-PDGF-B antibodies and methods of use for treating pulmonary arterial hypertension (PAH) |
| TW202540203A (zh) * | 2024-01-08 | 2025-10-16 | 日商中外製藥股份有限公司 | 結合pdgf-b與pdgf-d的抗原結合分子及使用方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| CA2509136C (en) | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| EP3168304A1 (en) * | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| DE102004062361A1 (de) * | 2004-12-10 | 2006-06-22 | Cocreate Software Gmbh & Co. Kg | Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern |
| CN105085678B (zh) * | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| KR20150023957A (ko) | 2012-06-28 | 2015-03-05 | 몰리큘라 파트너스 아게 | 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질 |
| SMT202100621T1 (it) * | 2012-07-13 | 2022-01-10 | Roche Glycart Ag | Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari |
| EP4566672A3 (en) * | 2012-11-08 | 2025-08-13 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| HK1216428A1 (zh) * | 2012-11-09 | 2016-11-11 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| HK1213578A1 (zh) | 2013-04-29 | 2016-07-08 | 豪夫迈‧罗氏有限公司 | 结合人fcrn的修饰的抗体和使用方法 |
| CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| WO2016075035A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| WO2016075037A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
-
2015
- 2015-11-06 AU AU2015345322A patent/AU2015345322A1/en not_active Abandoned
- 2015-11-06 RU RU2017120361A patent/RU2017120361A/ru not_active Application Discontinuation
- 2015-11-06 WO PCT/EP2015/075877 patent/WO2016075036A1/en not_active Ceased
- 2015-11-06 EP EP15791586.9A patent/EP3218400A1/en not_active Ceased
- 2015-11-06 KR KR1020177011693A patent/KR20170082520A/ko not_active Withdrawn
- 2015-11-06 SG SG11201703426PA patent/SG11201703426PA/en unknown
- 2015-11-06 BR BR112017009792A patent/BR112017009792A2/pt not_active Application Discontinuation
- 2015-11-06 MX MX2017005975A patent/MX2017005975A/es unknown
- 2015-11-06 CA CA2963723A patent/CA2963723A1/en not_active Abandoned
- 2015-11-06 CN CN201580058634.5A patent/CN107148429B/zh not_active Expired - Fee Related
- 2015-11-06 JP JP2017525016A patent/JP6946184B2/ja not_active Expired - Fee Related
- 2015-11-09 AR ARP150103646A patent/AR102593A1/es unknown
- 2015-11-09 TW TW104136908A patent/TW201630934A/zh unknown
-
2017
- 2017-03-20 IL IL251286A patent/IL251286A0/en unknown
- 2017-05-09 US US15/590,172 patent/US10087246B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017005975A (es) | 2017-06-29 |
| BR112017009792A2 (pt) | 2018-02-27 |
| US20170247440A1 (en) | 2017-08-31 |
| JP6946184B2 (ja) | 2021-10-06 |
| RU2017120361A (ru) | 2018-12-13 |
| EP3218400A1 (en) | 2017-09-20 |
| US10087246B2 (en) | 2018-10-02 |
| RU2017120361A3 (es) | 2019-05-29 |
| AU2015345322A1 (en) | 2017-04-06 |
| CN107148429A (zh) | 2017-09-08 |
| CN107148429B (zh) | 2021-12-03 |
| CA2963723A1 (en) | 2016-05-19 |
| KR20170082520A (ko) | 2017-07-14 |
| SG11201703426PA (en) | 2017-05-30 |
| WO2016075036A1 (en) | 2016-05-19 |
| TW201630934A (zh) | 2016-09-01 |
| JP2017534645A (ja) | 2017-11-24 |
| IL251286A0 (en) | 2017-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MY198942A (en) | Anti-tau antibodies and methods of use | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20150614A1 (es) | Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
| PE20180317A1 (es) | Anticuerpos anti-tau y metodos de uso | |
| JP2020500538A5 (es) | ||
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| NZ626520A (en) | Anti-lrp5 antibodies and methods of use | |
| PE20150945A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
| PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| PE20220392A1 (es) | Moleculas de union a claudina-6 y usos de las mismas | |
| PE20141693A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek | |
| AR103896A1 (es) | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| PE20161376A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |